Judy Sing-Zan Wang

机构：Sarah Cannon · ORCID：0000-0003-4789-4913

发表论文 193 篇 · 总被引 1649 次 · h-index 24

代表论文

Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies (2025 · Journal of Hematology & Oncology · 被引 27)
Phase 1/2, open-label study of oral bacterial supplementation (EDP1503) plus pembrolizumab in participants with advanced or metastatic microsatellite-stable colorectal cancer, triple-negative breast cancer, and checkpoint inhibitor–relapsed tumors (2025 · Investigational New Drugs · 被引 14)
Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial (2024 · Targeted Oncology · 被引 13)
Initial phase 1 dose escalation data for emiltatug ledadotin (Emi-Le), a novel B7-H4-directed dolasynthen antibody-drug conjugate. (2025 · Journal of Clinical Oncology · 被引 8)
TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11 -Mutant Tumors to Anti–PD-1 Immunotherapy (2025 · Cancer Research · 被引 7)
Open-Label, Multicenter, Phase I Study to Assess Safety and Tolerability of Adavosertib Plus Durvalumab in Patients with Advanced Solid Tumors (2024 · Targeted Oncology · 被引 7)